IBM Stock Falls 1.5% as Mainframe Slump Overshadows Quantum Progress

Date: August 20, 2026

Key Takeaways

• IBM shares fell 1.46% to $233.69, ending a two-session advance and remaining almost 30% below its June record high.
• Weak second-quarter results are a primary concern, with IBM Z revenue dropping 42% and infrastructure revenue falling 7%.
• The company has reduced its 2026 revenue-growth outlook, overshadowing progress in quantum computing and government software opportunities.

Stock Performance Overview

On August 20, IBM's stock closed at $233.69, down 1.46%, marking the end of a two-day winning streak. This decline occurred amidst a broader market downturn, with the S&P 500 and Dow Jones Industrial Average also experiencing losses. IBM's trading volume was notably low, indicating investor caution rather than panic.

Q2 Earnings Report Highlights

The pressure on IBM's stock can be traced back to disappointing earnings released in July. The final second-quarter report revealed a mere 1% year-on-year revenue increase to $17.16 billion, with adjusted earnings of $2.93 per share, both falling short of market expectations. Key segments showed significant weakness:

• Infrastructure revenue fell 7% to $3.8 billion.
• IBM Z mainframe revenue plummeted 42%.
• Distributed infrastructure grew by 37%, but this was insufficient to offset the mainframe losses.

IBM has lowered its full-year revenue-growth forecast to 4%-5% at constant currency, down from over 5%. While management maintains a positive outlook on free cash flow, investors are seeking evidence of revenue recognition from delayed transactions.

Legal Scrutiny and Headline Risks

The post-earnings sell-off has attracted legal scrutiny, with law firms investigating whether IBM misled investors regarding large-deal closures and the outlook for IBM Z. Although this does not imply any wrongdoing, it adds a layer of risk for shareholders.

Positive Developments in Quantum Computing and Software

Despite the mainframe challenges, IBM has made strides in other areas. Recent announcements include:

• Progress in quantum computing with the connection of two modular cryogenic units.
• FedRAMP Moderate authorization for the Maximo Application Suite for Government, providing a compliant cloud option for U.S. agencies.
• Expansion of distribution coverage in Europe through Arrow Electronics.

While these developments support IBM's long-term strategy, they have not yet translated into immediate financial improvements.

Analyst Sentiment and Future Outlook

Following the Q2 results, several analysts have cut their price targets for IBM, reflecting lowered confidence. However, the overall sentiment remains mixed, with a consensus of Moderate Buy among analysts. The average 12-month target suggests a potential upside, but the wide range of estimates indicates significant uncertainty.

Looking ahead, IBM's stock will likely be sensitive to signs of recovery in Q3, particularly in terms of deal closures and software growth. A convincing improvement in performance could help restore investor confidence, while further guidance reductions or legal issues could lead to renewed selling pressure.

Conclusion

IBM's current challenges, particularly in its mainframe business, overshadow its advancements in quantum computing and software. Investors are closely monitoring the company's ability to navigate these issues and deliver on its growth forecasts.